Navigation Links
TorreyPines Therapeutics Announces its Board of Directors' Approval of Plan of Liquidation and Dissolution
Date:5/29/2009

LA JOLLA, Calif., May 29 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that its Board of Directors has determined, after consideration of potential strategic and financing alternatives, that it is in the best interests of the Company and its stockholders to liquidate the Company's assets and to dissolve the Company. The Company's Board of Directors has unanimously approved a Plan of Liquidation and Dissolution of the Company (the "Plan of Dissolution") subject to stockholder approval. The Company intends to hold a special meeting of the stockholders to seek approval of the Plan of Dissolution and today it filed related proxy materials with the Securities and Exchange Commission (the "SEC").

Although the Board of Directors has approved the Plan of Dissolution, the Company continues to seek and will consider any reasonable alternative strategic or financing proposals presented to the Company. The investment firm Merriman Curhan Ford remains engaged as the Company's financial advisor to assist in the evaluation of strategic options, including the possible sale of the Company or its AMPA/kainite receptor antagonist product candidates.

The Plan of Dissolution contemplates an orderly wind down of the Company's business and operations. If the Company's stockholders approve the Plan of Dissolution, the Company intends to file a certificate of dissolution, satisfy or resolve its remaining liabilities and obligations, including any contingent liabilities and costs associated with the liquidation and dissolution and make reasonable provisions for unknown or unresolved claims and liabilities, if any. Following stockholder approval of the Plan of Dissolution and the filing of the certificate of dissolution, the Company plans to delist its common stock from the Nasdaq Global Market.

IMPORTANT A
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine ... and immunotherapy company, today announced that the U.S. ... for Fast Track designation and Phase I clinical ... conjunction with the mutual co-development agreement signed with ... Fast Track designation for the DPX-Survivac. , “We ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Cytokinetics, Incorporated ... on February 28 with patients and health care advocates ... for Rare Disease Day®. Rare Disease Day is ... calling attention to the special challenges faced by patients ... , “Cytokinetics is proud to stand alongside patients and ...
(Date:2/26/2015)... Feb. 26, 2015  23andMe, the leading personal genetics ... as Privacy Officer and Corporate Counsel. Black brings ... laws as well as health care regulations. As a ... be responsible for reviewing, updating and enhancing the company,s ... and abroad. She joined the company January 5, 2015 ...
(Date:2/26/2015)... LAUDERDALE, Fla. , Feb. 26, 2015 ... discussed growth priorities driven by key research advancements and ... segments at today,s Bank of America Merrill Lynch 2015 ... met the challenge of building grain supplies the last ... to continue at the pace of the last decade, ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 623andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5
... parameter at the upcoming World ... Congress of Anesthesiologists Meeting, IRVINE, ... and Measure-Through Motion and Low Perfusion pulse,oximetry, announced that ... total hemoglobin (SpHb(TM)) and oxygen content,(SpOC(TM)) monitoring at the ...
... 25 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... first Phase 3 clinical trial with AZ-004 ... being developed for the treatment of,acute agitation ... Alexza,believes the novel, non-invasive nature and rapid ...
... Germany, February 25 t2cure, a clinical,stage biopharmaceutical ... cells, announced today that it has appointed,Dr. Petra ... pleased to have Petra join our company", said ... research and project,management will be of critical importance ...
Cached Biology Technology:Masimo Announces Continuous Noninvasive Total Hemoglobin 2Masimo Announces Continuous Noninvasive Total Hemoglobin 3Masimo Announces Continuous Noninvasive Total Hemoglobin 4Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations 2
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
(Date:2/5/2015)... VIEW, Calif. , Feb. 3, 2015 /PRNewswire/ ... printer technology, demand from industries such as consumer ... global market for surface mount technology (SMT) screen ... equipment to automatic control will push the adoption ... dispensers will remain steady as glue dispensers are ...
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... - The growth in China,s carbon dioxide (CO2) emissions ... stabilizing atmospheric greenhouse gases even more difficult, according to ... California, Berkeley, and UC San Diego. Previous estimates, ... Change, say the region that includes China will see ...
... Research Prize and Medal will be awarded to Philip R. ... of Overseers and NJIT President Robert A. Altenkirch on March ... Solar-Terrestrial Research which has led a five-year project to build ... Observatory (BBSO), Big Bear Lake, CA. First light ...
... was not geographically isolated 25 million years ago ... demonstrated by researchers from the Laboratoire des Mcanismes ... Toulouse 3/IRD) and the Palobiodiversit et paloenvironnements laboratory ... results were obtained thanks to analyses of the ...
Cached Biology News:Alarming growth in expected CO2 emissions in China, finds UC analysis 2Alarming growth in expected CO2 emissions in China, finds UC analysis 3NJIT overseers to award NJIT physicist new medal and prize 2A fossilized giant rhino bone questions the isolation of Anatolia, 25 million years ago 2
... PRODUCT SPECIFICATIONS Form: White powder Assay: 1.5 - 2.0 Bleomycin ... 6.0 Loss On Drying: less than or equal to 6.0% ... A 2 : 55 - 70% B 2 : 25 ... or equal to 90% B 4 : less than or ...
... High Vacuum pumps deliver critical performance for ... ballast control optimizes pump performance to suit ... allows for convenient checking of proper oil ... of pumps is designed to work with ...
6 x Blend of rTth DNA Polymerase and Tli to provide optimized amounts of both 5-3 and 3-5 proofreading activity...
This spacer is required to use the Miniature FRENCH Pressure Cell (FA-003) with the Laboratory Press....
Biology Products: